Immune checkpoint inhibitors have transformed lung cancer therapy, offering durable tumour control and improved survival. Yet their success has revealed a paradox: checkpoint inhibitor-related pneumonitis (CIP), an unpredictable immune-mediated complication th... ...

请注册登录后继续浏览